Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is poised for success with their potential breakthrough drug, roluperidone, in a market that is projected to be worth $1.9B. Despite regulatory risks and a 65% chance of success, the company has optimized their Phase 3 trial for success and the drug has shown promising results in reducing negative symptoms of schizophrenia and improving cognitive function. While there was a higher than expected loss in the fourth quarter, Minerva has enough funds for their operating plans and the potential for strong sales in the future.

Bears say

Minerva Neurosciences is a clinical-stage biopharmaceutical company with a negative outlook due to the company's unimpressive financial metrics, including a history of losses and uncertainty around future profitability. Additionally, the recent Phase 3 trial for their lead product candidate, Roluperidone, did not meet its primary endpoint and had a high placebo response, raising concerns about its potential efficacy. The company's valuation and stock price may also be affected by clinical trial results, regulatory and approval risks, and the need for additional funding.

Minerva Neurosciences (NERV) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Hold based on their latest research and market trends.

According to 2 analysts, Minerva Neurosciences (NERV) has a Hold consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.